TY - JOUR T1 - Blockade of Vascular Endothelial Growth Factor Receptor Signal Pathway and Antitumor Activity of ON-III (2′,4′-Dihydroxy-6′-methoxy-3′,5′-dimethylchalcone), a Component from Chinese Herbal Medicine JF - Molecular Pharmacology JO - Mol Pharmacol SP - 1444 LP - 1450 DO - 10.1124/mol.104.009894 VL - 67 IS - 5 AU - Xiao-Feng Zhu AU - Bin-Fen Xie AU - Jun-Min Zhou AU - Gong-Kan Feng AU - Zong-Chao Liu AU - Xiao-Yi Wei AU - Feng-Xian Zhang AU - Mei-Fang Liu AU - Yi-Xin Zeng Y1 - 2005/05/01 UR - http://molpharm.aspetjournals.org/content/67/5/1444.abstract N2 - Antiangiogenesis is a promising strategy of cancer treatment. Vascular endothelial growth factor receptor [fetal liver kinase/kinase-inserting domain-containing receptor (KDR)] is a tyrosine kinase receptor and has been strongly implicated in tumor angiogenesis. In this study, we report that 2′,4′-dihydroxy-6′-methoxy-3′,5′-dimethylchalcone (ON-III), extracted from the dried flower Cleistocalyx operculatus, used in traditional Chinese medicine, reversibly inhibited KDR tyrosine kinase phosphorylation, but epidermal growth factor receptor tyrosine kinase phosphorylation was unaffected under the same concentrations of ON-III. ON-III also inhibited mitogen-activated protein kinase (MAPK) and AKT activation of KDR signal transduction in downstream molecules without reduced total MAPK and AKT. The results in vitro showed that ON-III inhibited growth of human vascular endothelial HDMEC cells in the presence of VEGF preferentially, compared with epidermal growth factor. Systemic administration of ON-III at nontoxic doses in nude mice resulted in inhibition of subcutaneous tumor growth of human hepatocarcinoma Bel7402 and lung cancer GLC-82 xenografts. The tumor vessel density decreased, as determined by immunohistochemical staining, for CD31 after ON-III treatment. These results indicated that ON-III inhibited KDR tyrosine kinase, shut down KDR-mediated signal transduction, and inhibited tumor growth of human xenografts in vivo. ER -